Brief: Bellicum Reports Safety Results For Pancreatic Cancer Drug
14/12/2018 12:11
Dec 14 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM REPORTS SAFETY RESULTS AND PROMISING ACTIVITY OF
ITS
CONTROLLED CAR-T CANDIDATE BPX-601 IN PATIENTS WITH ADVANCED
PANCREATIC CANCER AT ESMO-IO
* BELLICUM PHARMACEUTICALS INC - BPX-601 WAS WELL-TOLERATED
WITH
NO CRS OR NEUROTOXICITY REPORTED IN INITIAL CELL-DOSE ESCALATION
* BELLICUM PHARMACEUTICALS INC - INITIAL EVIDENCE OF
BIOLOGIC
ACTIVITY AND STABLE DISEASE OBSERVED IN SOME PATIENTS WITH
SINGLE RIMIDUCID DOSE
* BELLICUM PHARMACEUTICALS INC - RIMIDUCID-ACTIVATED
GOCAR-T(®)
RESULTED IN SIGNIFICANT EXPANSION AND PERSISTENCE OF T CELLS
* BELLICUM PHARMACEUTICALS INC - TO ADD ADDITIONAL TUMOR
TYPES IN
PART 2 OF STUDY, INCORPORATING STANDARD LYMPHODEPLETION AND
REPEAT RIMIDUCID DOSING
* BELLICUM PHARMACEUTICALS INC - LOOK FORWARD TO REPORTING
UPDATED
RESULTS OF BPX-601 STUDY IN 2019
Source text for Eikon: ID:nGNX225hsQ
Further company coverage: BLCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview